M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance PharmaphorumInsilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates.NeuroscienceRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum Insilico Medicine has teamed up with SK Biopharmaceuticals on a wide-ranging, $2.5bn partnership to use AI to find neuroimmune drug candidates. Neuroscience Read full story Post navigation Previous: Post-marketing oncology studies: Enabling faster recruitment and lower costsNext: Boehringer advances duo for aggressive cancers into phase 3 Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026